Literature DB >> 27878559

Impact of Drug Manipulation on Seizure Freedom in Adults with Uncontrolled Epilepsy: A Prospective Controlled Study in Rural China.

Xiaoting Hao1, Ziyi Chen2, Bo Yan1, Patrick Kwan3,4,5, Dong Zhou6.   

Abstract

INTRODUCTION: It has been suggested that uncontrolled epilepsy might not necessarily equate to drug resistance when antiepileptic drugs (AEDs) are used at relatively low doses, a practice frequently observed in rural areas of China.
OBJECTIVE: To assess the clinical benefits of further drug manipulation in this situation, we prospectively followed up the outcomes of patients with uncontrolled epilepsy while taking relatively low doses of AEDs.
METHODS: The study included patients aged 16 years and older with uncontrolled epilepsy and who were receiving at least one AED at a dosage below 50% of the World Health Organization (WHO) defined daily dose (DDD) (50% DDD) (Group 1). Patients with drug-resistant epilepsy were included for comparison (Group 2). Both groups were followed-up for at least 2 years. Seizure outcomes after further drug manipulations were recorded at the last follow-up.
RESULTS: A total of 197 patients (55.3% male) were included in Group 1 and 32 (46.9% male) in Group 2; their mean duration of follow-up was 28.85 ± 1.90 and 30.91 ± 2.04 months, respectively. At the last follow-up, 16.8% (33/197) of patients in Group 1 had become seizure-free compared with none in Group 2 (p < 0.001). Seventeen of 93 (18.3%) patients in Group 1 became seizure free after increasing the dosage of baseline AED(s) alone. Only 5.5% (3/55) of patients who had failed to respond to an AED at ≥50% DDD at baseline became seizure free compared with 21.1% (30/142) who did not have such a history (p = 0.001). The number of AEDs taken at a dosage below 50% DDD at baseline was not associated with seizure outcome.
CONCLUSIONS: Uncontrolled epilepsy could become controlled in a substantial proportion of patients by dose increase alone, particularly if there is no history of drug failure at ≥50% DDD.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27878559     DOI: 10.1007/s40263-016-0397-5

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  17 in total

1.  Reduction in polypharmacy for epilepsy.

Authors:  S D Shorvon; E H Reynolds
Journal:  Br Med J       Date:  1979-10-27

2.  Results of treatment changes in patients with apparently drug-resistant chronic epilepsy.

Authors:  Anna L Luciano; Simon D Shorvon
Journal:  Ann Neurol       Date:  2007-10       Impact factor: 10.422

3.  Enhancing medical compliance of patients with convulsive epilepsy in rural community: a randomized intervention trial.

Authors:  Juan Li; Yang Si; Jia Hu; Ling Liu; Ying Deng; Jun He; Ning-Mei Zhang; Dong Zhou
Journal:  Epilepsia       Date:  2013-09-30       Impact factor: 5.864

4.  Causes of death among people with convulsive epilepsy in rural West China: a prospective study.

Authors:  J Mu; L Liu; Q Zhang; Y Si; J Hu; J Fang; Y Gao; J He; S Li; W Wang; J Wu; J W Sander; D Zhou
Journal:  Neurology       Date:  2011-06-08       Impact factor: 9.910

Review 5.  Antiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adults.

Authors:  Linda J Stephen; Martin J Brodie
Journal:  Curr Opin Neurol       Date:  2012-04       Impact factor: 5.710

6.  Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies.

Authors:  Patrick Kwan; Alexis Arzimanoglou; Anne T Berg; Martin J Brodie; W Allen Hauser; Gary Mathern; Solomon L Moshé; Emilio Perucca; Samuel Wiebe; Jacqueline French
Journal:  Epilepsia       Date:  2009-11-03       Impact factor: 5.864

7.  The prevalence and treatment gap in epilepsy in China: an ILAE/IBE/WHO study.

Authors:  W Z Wang; J Z Wu; D S Wang; X Y Dai; B Yang; T P Wang; C L Yuan; R A Scott; L L Prilipko; H M de Boer; J W Sander
Journal:  Neurology       Date:  2003-05-13       Impact factor: 9.910

8.  Uncontrolled epilepsy is not necessarily the same as drug-resistant epilepsy: differences between populations with newly diagnosed epilepsy and chronic epilepsy.

Authors:  Xiaoting Hao; Danielle Goldberg; Kevin Kelly; Linda Stephen; Patrick Kwan; Martin J Brodie
Journal:  Epilepsy Behav       Date:  2013-08-01       Impact factor: 2.937

9.  Reduction of two-drug therapy in intractable epilepsy.

Authors:  D Schmidt
Journal:  Epilepsia       Date:  1983-06       Impact factor: 5.864

10.  The ILAE/IBE/WHO epilepsy global campaign history. International League Against Epilepsy. International Bureau for Epilepsy.

Authors:  E H Reynolds
Journal:  Epilepsia       Date:  2002       Impact factor: 5.864

View more
  2 in total

1.  Adverse drug reactions associated with six commonly used antiepileptic drugs in southern China from 2003 to 2015.

Authors:  Yanru Du; Jiahe Lin; Jingzan Shen; Siqi Ding; Mengqian Ye; Li Wang; Yi Wang; Xinshi Wang; Niange Xia; Rongyuan Zheng; Hong Chen; Huiqin Xu
Journal:  BMC Pharmacol Toxicol       Date:  2019-01-14       Impact factor: 2.483

2.  A cascade of care for people with epilepsy: learning from "HIV/AIDS 90-90-90".

Authors:  Farrah J Mateen
Journal:  Gates Open Res       Date:  2019-08-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.